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Abstract: Diabetes mellitus is a pandemic metabolic disease characterized by chronically elevated blood 
glucose concentration due to insulin dysfunction. Diabetics are prone to limbs fungal infections and ulcers due 
to vascular injury and end-organ damage such as nephropathy, retinopathy and neuropathic pain all of which 
are associated with methylglyoxal elevation. Methylglyoxal is generated through carbohydrate, lipid and 
protein metabolism which are all found to be exacerbated in diabetes. Moreover, methylglyoxal is highly 
reactive with various cellular and interstitial molecules such as proteins and phospholipids to form stable 
adducts and advanced glycation end products. Methylglyoxal induces insulin resistance, pancreatic β-cells 
cytotoxicity, and induces endothelial dysfunction that accelerates retinopathy, another diabetes complication. 
Additionally, methylglyoxal induces hyperalgesia and neuronal inflammation associated with neuropathic pain. 
Therefore, methylglyoxal might represent a potential therapeutic target in diabetes and associated 
complications. 
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1. Introduction: 
Diabetes mellitus (DM) is a pandemic metabolic disease characterized by chronically 
elevated blood glucose concentration (hyperglycaemia) due to insulin dysfunction which is 
attributed to insufficient -or blunted- insulin secretion and/or declined tissue sensitivity to 
insulin1. The incidence of diabetes mellitus is increasing throughout the world and numbers 
are expected to reach 592 million by the year 2035, mainly because of the increase in 
obesity2. Approximately 50% of diabetics show diabetes complications by the time when 
they are diagnosed3. Approximately 5 million people died from diabetes in 2014 globally 
which accounts for a death every 7 seconds4. Despite the differences in aetiology, clinical 
presentation, and disease prevalence, secondary complications, such as neuropathic pain, 
occur in both type 1 and 2 diabetes mellitus5. Diabetes complications lead to a reduced 
quality of life posing a huge economic burden to the health system and society5. In 2011 in 
the UK, the NHS spent almost £24 billion on diabetes, 30% of which was spent on managing 
complications, such as neuropathic pain. By 2035, it is estimated that diabetes will cost the 
NHS approximately £40 billion, accounting for 17% of total health resource expenditure6.  
Among diabetic patients approximately 10% are diagnosed with type-1-DM (T1DM) which is 
mainly attributed to autoimmune activity where expressed plasma islet-cells antibodies 
destroy pancreatic β-cells1, 7. Children, under 12 years comprise the majority of T1DM 
patients who require life-long insulin treatment for survival. However, there are two types 
of monogenic diabetes which are commonly misdiagnosed as T1DM due to early onset of 
disease. These are neonatal diabetes (ND) which is diagnosed in the first 6 months of life, 
whereas the second type; maturity-onset diabetes of the young (MODY) affects individuals 
younger than 25 years, controlled largely through the use of sulphonylureas such as 
glibenclamide7.  
The large majority of diabetics, are of type-2-DM (T2DM), which is regarded as a complex 
disease that embraces genetic factors, lifestyle, age, obesity, pregnancy and gender as risk 
factors8. Unlike T1DM, patients of T2DM usually do not require insulin to survive since 
insulin secretion is only partially deficient and/or the individual is insulin resistant. Insulin 
resistance is mainly attributed to chronically elevated levels of insulin reducing sensitivity 
and further increased by abdominal fat and hence obesity1. Reduced insulin secretion may 
be due to insulin signalling cascade alteration and/or reduced pancreatic β-cells mass, 
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however, the extent of pancreatic β-cells mass reduction is controversial as some studies 
stated that 65% loss of pancreatic β-cells is sufficient to induce diabetes9 while other studies 
concluded that 10% reduction of pancreatic β-cells mass is also associated with numerous 
altered insulin signalling components that initiate diabetes10. 
2. Methylglyoxal and diabetes: 
In addition to the previously mentioned diabetes complications, diabetics suffer from 
frequent: thirst (polydipsia), urination (polyuria) and hunger (polyphagia)1 , these common 
complications are recently found to be associated with plasma/tissue methylglyoxal (MGO) 
elevation (Table 1). 
Chronic hyperglycaemia is the main DM complication where blood glucose concentration 
exceeds 7mmol/L (125mg/dl). This results in an increasing proportion of glucose metabolism 
(approximately 0.5% of glycolysis), passing down alternate pathways to generate reactive 
oxygen species (ROS) such as MGO that is highly reactive with various cellular and interstitial 
molecules such as proteins and phospholipids to form stable adducts and advanced 
glycation end products (AGE)11 12. Upon forming AGE, MGO is trapped intracellularly and 
subsequently increases oxidative stress (OS) that disrupts the cellular membrane integrity 
and thereby allows MGO leakage to the serum from where it can be measured for disease 
progression and severity11 13 14. Physiological human plasma MGO concentration is 
approximately 150nM and is doubled in T2DM patients’ plasma15. Moreover, glycolysis-
derived MGO interacts with cellular proteins and nucleic acids to accelerate AGE production 
resulting in pancreatic β-cell cytotoxicity. This exacerbates hyperglycaemia and hence DM 
complications11. However, clinical studies have failed to significantly correlate MGO to blood 
glucose concentration due to 2 main technical reasons, (i) firstly it is essential to dissociate 
MGO from protein without causing any DNA damage and/or oxidation to accurately 
measure total MGO, and (ii) the heterogeneity of the samples due to diverse patient 
backgrounds14.  
 
 
 
4 
 
 
2.1. MGO sources: 
Being an AGE precursor, MGO levels have been widely studied14. The 4 main MGO sources 
are summarized in the following formula: 
MGO total = MGO carbohydrates + MGO lipids + MGO proteins + MGO exogenous  
As shown in figure 1, three main integrated metabolic pathways are involved in MGO 
formation: 
1. Carbohydrates: 
Reducing sugars are able to react with proteins’ amino groups to yield Schiff’s base 
which is structurally rearranged into Amadori product to be subjected to series of 
reactions that generate AGE12. Accordingly, MGO is generated mainly through 
phosphorylating glycolysis such as triose-phosphate enzymatic metabolism which 
was found to be increased in hyperglycaemia, the pentose phosphate shunt, sorbitol 
pathways such as xylitol metabolism and fourthly glucoxidation14 16. Moreover, 
triose-phosphate accumulation is involved in diabetic nephropathy revealing the 
involvement of carbohydrate generated MGO pathway in diabetes complication and 
such a pathway was shown to be inhibited through thiamine17 18 (figure 1). 
 
2. Lipid pathways: 
Lipid peroxidation of polyunsaturated fatty acids yields short chain; 3-9 carbon long 
fragment molecules of highly reactive aldehyde such as 2-Alkenol, 4-hydroxy-2-
alkenal as well as ketoaldehydes from which glyoxal compounds such as MGO is 
generated from non-enzymatic and enzymatic metabolism of acetoacetate or 
acetone intermediates, respectively12 14. Acetoacetate is a major ketone body (KB) 
elevated in type 2 diabetics’ plasma19.  Moreover, lipolysis shares a common 
intermediate with carbohydrate metabolism; triose-phosphate through α-glycero-
phosphate dehydrogenase-metabolized glycerol14. Previous studies found that 
lipolysis is increased in diabetes and suppression of lipolysis improves insulin 
sensitivity and glucose utilization20 21. Moreover, isopropyl alcohol (IP) is significantly 
increased (5mg/dl) in ketoacidosis diabetic plasma22. IP is a metabolite of acetone, as 
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the reaction is governed by alcohol dehydrogenase which favours the production of 
IP when acetone is increased as in diabetes mellitus where glucose utilization is 
compromised, and the body adapts the energy supply toward fatty acid oxidation 
through NAD+ reduction into NADH. Therefore, when NADH/NAD+ ratio is increased, 
NADH is utilized to produce IP from acetone22 23. 
 
3. Protein metabolism: 
Numerous in vitro studies demonstrate the vulnerability of tyrosine, serine, 
threonine and glycine rich proteins toward oxidation as these residues are 
enzymatically converted to acetone and aminoacetone intermediates which are 
converted into MGO12 14. Moreover, semi-carbazide sensitive amine oxidase (SSAO) 
which converts aminoacetone into MGO and hydrogen peroxide is the only enzyme 
found elevated in diabetic plasma14. Protein catabolism is increased by 
approximately 50% in streptozotocin treated rats, and this increased rate of protein 
catabolism is attributed to insulin resistance and increased glucocorticoids 
production in normal rats24.  
 
4. Exogenous MGO: 
AGE are ingested through heated and processed fats, proteins (Maillard reaction) as 
well as sugars and tobacco25, whereas previous studies revealed that coffee and 
whiskies are the main MGO-containing beverages26 27. The average daily 
consumption of AGE is  
16000kU AGE (kilo unit AGE per gram of serving size) which is even aggravated by 
high temperature processing such as oven frying that increases the AGE content of 
chicken breast to 900kU/g compared to boiled chicken breast  
(100kU AGE/g)28. Chronic consumption of AGE-containing food/beverages causes 
mild liver inflammation as well as fat disposition on parenchymal cells which alters 
fasting insulin and thereby reduces glucose tolerance according to previous research 
conducted on rat hepatocytes 27. In the Maillard reaction, reducing sugars such as 
glucose interact with free amino groups found in proteins to form for instance  
N-substituted glycosylamine which in the presence of water goes through Amadori 
rearrangement to yield Amadori product, 1-amino-1-deoxy-2-ketose29. The 
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rearranged Amadori product (RAP) is then degraded through 2,3 enolisation to form 
numerous fission products such as acetol, pyruvaldehyde and diacetyl compounds at 
pH˃729. These carbonyl compounds are highly reactive with amino acids to form 
aldehydes and α-aminoketones29. Previous studies found that Maillard reaction 
products are significantly increased in diabetics’ skin collagen as Nε-carboxymethyl 
lysine (CML), fructoselysine (FL) and pentosidine which are associated with 
accelerated aging30. Additionally, CML is significantly elevated in diabetic plasma 
when compared to healthy plasma, and such elevation is exacerbated when purely 
prepared AGE beverages were ingested22. This elevation was associated with altered 
vascular function through supressing the expression and function of eNOS as well as 
stimulating the release of vascular cells adhesion molecules (VCAM-1)25.  
 
2.2. MGO metabolism:  
Two glutathione (GSH) dependent pathways contribute to MGO metabolism; glyoxalase 
system (GLO), glyoxalase 1 and glyoxalase 2 (GLO1 & GLO2) and aldose reductase, of which 
GLO-1 is the major pathway that converts MGO it to non-toxic D-lactate14 31. However, as 
11% of glucose is metabolized through the sorbitol pathway, the bi-modal aldose reductase 
acts as aldehyde reductase rather than ketone reductase and thereby preferentially 
produces acetol which thereafter is converted retrospectively to MGO through CYP2E1 to 
start a futile cycle that depletes the intracellular GSH and elevates acetol in diabetic 
plasma14. 
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Figure 1 Endogenous sources of methylglyoxal (MGO) from glucose, lipid and protein metabolism. (A) Normal 
non-diabetic condition shows low MGO production from un-affected glycolysis, lipolysis or proteolysis with 
major sources represented in bold arrows. (B) Diabetes is associated with increased MGO production from 
hyperglycaemia, accelerated lipolysis and proteolysis represented with thick borders and bold arrows which 
are accompanied with compromised glyoxalase activity. 
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2.3. MGO and insulin: 
Insulin secretion is a calcium-dependent cascade which starts when pancreatic β-cells 
glucose-transporter-1 (GLUT-1) take up glucose due to elevated plasma-glucose. This results 
in ATP synthesis and potassium ATP channel (KATP) closure. Once KATP are closed, Calcium 
ions (Ca+2) enter through Voltage gated Ca+2 channels initiating insulin exocytosis32. 
However, glucose is not the only insulin release stimulator as lipids and proteins are also 
insulin secretagogues, in addition to other neurotransmitters and hormones such as 
incretins which stimulate insulin secretion independently from Ca+2 as illustrated in figure 
27. 
Insulin resistance is a complex condition where a normal insulin concentration is not 
sufficient to mediate glucose uptake and utilization due to insulin signalling disruption and 
hence, more insulin is released to try to maintain glucose homeostasis33 34. MGO has been 
shown to bind with insulin through targeting arginine residues located in chain B and at N-
terminus33. Subsequently, MGO-modified insulin chain B is heavier than free insulin by an 
additional 126Da resulting in less glucose uptake and utilization. This has been 
demonstrated in skeletal muscle L8 cells and 3T3-L1 adipocytes as well as a 50% reduction in 
metabolism in H4-II-E hepatocytes33. This study is further supported by the fact that insulin 
receptor substrate-1 (IRS-1) phosphorylation and PI3K activity are both suppressed dose 
dependently following MGO and reversed with MGO scavenger; N-acetylcysteine34 (Table 
1). Moreover, MGO (100μM) induces pancreatic β-cytotoxicity when applied to RINmf5 
insulin secreting cells in culture11. Such an effect is comparable to a high glucose (16mM) apoptotic 
effect on rat pancreatic β-cells11. These findings suggest that MGO might play a major role in 
progressive stages of diabetes where chronic hyperglycaemia yields elevated MGO that reduces 
insulin signalling and pancreatic β-cells numbers leading to a further reduction in insulin secretion11 
(Figure 2). Moreover, when MGO 60mg/kg/day was infused in Sprague-Dawley rats for 28 days, it 
resulted in a significant reduction in plasma insulin and a significant increase in fasting plasma 
glucose. Additionally, plasma and pancreatic, muscle and, adipocyte tissues were all characterized by 
significant MGO elevation associated with significant decrease in glutathione (GSH) and adipocyte 
plasma membrane glucose transporter-4 (GLUT-4) as well as pancreatic GLUT-2 35. 
Insulin binds to its corresponding tyrosine-kinase coupled endothelial receptor, insulin receptor (IR) 
which is phosphorylated and provides a docking site for insulin receptor substrate-1 (IRS-1) to bind. 
As it exerts tyrosine-kinase activity, IR phosphorylates IRS-1 to unveil an interactive sulfhydryl 
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(SH2) domain which is responsible for activating phosphatidylinositol 3-kinase /protein 
kinase B (PI-3K/PKB) as well as Ras-mitogen activated protein kinase (MAPK) pathways. 
These pathways phosphorylate approximately 40 cellular targets including Akt-dependent 
endothelial nitric oxide synthase (eNOS) that generates nitric oxide (NO) to yield 
endothelium-dependent vasodilation34 36 37 38. Therefore, MGO-induced insulin dysfunction 
(reduced secretion and increased resistance) might directly cause vascular dysfunction, a 
common complication in diabetes37 (Figure 3). 
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Figure 2 Insulin release from pancreatic β-cells through calcium dependent and independent pathways.  
GLUT-1 takes up glucose which is metabolised through glucokinase (GCK) to glucose-6-phophate which is 
metabolised in the mitochondria to generate ATP.  A rise in [ATP] stimulates the closure of potassium ATP 
channels and depolarisation that triggers Ca+2 influx. Whereas glucagon like peptide-1 (GLP-1) stimulates 
insulin secretion via an exchange protein activated by cAMP (EPAC) and protein kinase A (PKA)-dependent 
mechanism which are activated through cyclic adenosine monophosphate (cAMP). Plus signs reveal 
stimulation. (A) normal insulin secretion. (B) Methylglyoxal (MGO) is toxic to pancreatic β-cells and forms 
insulin-adducts which endows insulin with higher molecular weight and less activity. 
 
 
 
2.4. MGO and vasculature: 
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Numerous authors correlate highly accumulated MGO to vascular and other end organ 
damage such as nephropathy and neuropathy39. Vascular dysfunction is a common 
complication in DM which may culminate with renal failure, blindness and limb 
amputation40 41. 
As a highly reactive aldehyde MGO forms stable adducts when reacting with multiple 
macromolecules through preferentially targeted aminoacids as for instance lysine;  
Nε-carboxyethyl lysine (CEL), MGO-derived lysine-lysine dimer (MOLD), arginine; 5-
methylimidazolone, tetra-hydropyrimidine and argpyrimidine as well as sulfhydryl group-
containing cysteine which forms stabilized S-lactyl cysteine through keto-enol tautoumerism 
from which CEL and MOLD are both elevated in DM12. Accordingly, MGO inhibits eNOS 
through inhibiting the phosphorylation of serine 1177, thereby inhibiting NO production and 
yielding vascular dysfunction40 (Figure 3). Moreover, rat thoracic aortic smooth muscle cells 
(ASMC) treated with MGO (100μM) induces NO production and upon further investigations, 
the researchers found that H2O2 generation was also enhanced39. Furthermore, induced NO 
reacts with peroxides (O.2) forming the highly reactive oxidant peroxynitrite (ONOO-) so that 
NO is bound and thereby physiologically non-functional. In addition, ONOO- itself is 
considered as an essential atherosclerotic factor39. Furthermore, immunohistochemical-
based observations in kidneys from diabetic patients show increased argpyrimidine 
formation in patient arteries  suggesting MGO induces arterial injury as a further DM 
complication42. Vascular function restoration in GLO-1-overexpressed STZ treated animals is 
accompanied by MGO and AGE reduction and another study showed vascular function 
restoration through MGO scavengers such as diacetyl cysteine40 41 (Table 1).  
MGO is also a redox-based cell signalling regulator39, which oxidizes GSH to GSSH through 
irreversible binding to arginine and thereby alters the cellular redox system which pushed 
the cell toward oxidative stress-induced apoptosis33.  
MGO blocks insulin-stimulated eNOS phosphorylation at serine-1177 and threonine-497 and 
also inhibited tyrosine phosphorylation of IRS-1 and Akt37. GLO-1 inhibition results in 
elevation of MGO and showed similar inhibitory effects on eNOS, IRS-1 and Akt 
phosphorylation. Moreover, in vivo studies on mice administered i.p MGO 50-75mg/kg/day 
for 5 consecutive days/week for 7 weeks showed significant insulin resistance accompanied 
with compromised endothelial function that was attributed to IRS-1 inhibition through 
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serine-616 phosphorylation and eNOS signalling suppression37 (Figure 3). Additionally, 
endothelial dysfunction is accompanied by an increase in oxidative stress markers such as 
the vascular monocytes chemoattractant peptide-1 (MCP-1) and RAGE expression in Wistar 
and Goto-Kakizaki rats43. Tetrahydropyrimidine (THP), an AGE product of MGO was elevated 
in T1DM compared to non-diabetics (115.5U/μl vs 109.8U/μl) and such elevation was 
strongly associated with an endothelial dysfunction marker, soluble vascular cell adhesion 
molecule-1 (sVCAM-1) and phospholipase-A2 (sPLA2), a low grade inflammatory marker. 
This data suggests MGO as a diabetic marker for vascular dysfunction44. 
These diabetic vascular complications are commonly associated with retinopathy. MGO-
derived CML, CEL and hydroimidazalone-1 (MG-H1) are increased in diabetic wild type (WT) 
rat retina but not in diabetic GLO-1 overexpressing transgenic rats or in non-diabetic rats. 
GLO-1 overexpression prevented the generation of new capillaries in acellular tissues in 
central and peripheral regions of retina as well as preventing cellular capillary 
degeneration45. 
In addition to all these vascular complications, the lifespan of erythrocytes (RBC) is reduced 
in diabetes. The MGO concentration is doubled in diabetics’ RBC and elevated by fourfold in 
diabetics’ plasma compared to non-diabetics’46. MGO accelerates RBC suicidal death, 
eryptosis through enhancing phosphatidylserine exposure on the cell surface, a signal that 
triggers cell death. Further, MGO was shown to reduce ATP and GSH levels in RBCs which 
would accelerates eryptosis46 47. Moreover, ROS increment in haemodialysis patients (HD) 
reveals that cell injury is a major factor that corresponds to ROS leakage and plasma ROS 
increment, a fact that is supported by recent studies showing ROS such as methylglyoxal 
induces RBC injury14 48. 
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Figure 3 Methylglyoxal (MGO) induces vascular dysfunction by interfering with insulin signalling. (A) Normal 
endothelial vasodilation stimulated through insulin binding to its insulin receptor (IR) which is phosphorylated 
to unveil intracellular binding site for insulin receptor substrate-1 (IRS-1) which is phosphorylated upon 
binding. Phosphorylated IRS-1 provides a sulfhydryl (SH2) residue which is then bound with 
phosphatidylinositol 3-kinase (PI3K) that phopsphorylates protein kinase B (PKB) which phosphorylates and 
activates Akt that activates endothelial nitric oxide synthase to generate nitric oxide (NO).  NO diffuses into 
smooth muscle cells (SMCs) causing vasodilation (VD). (B) MGO reduces insulin secretion through pancreatic β-
cells toxicity, binds to insulin forming the less active insulin-MGO adduct and inhibiting eNOS phosphorylation 
which results in less NO production and compromised endothelial vasodilation.  
 
 
B 
A 
14 
 
2.5. MGO and neuropathic pain:  
Diabetes is one of the leading causes of chronic neuropathic pain 5. Neuropathic pain occurs 
in both Type 1 and Type 2 diabetics and given the heterogeneity of mechanisms that drives 
neuropathic pain in patients and over time, it is challenging to identify an optimum 
treatment strategy5. Among the major diabetic complications is diabetic neuropathy where 
nociception is exacerbated due to diabetes13. A recent study found diabetic plasma MGO 
was approximately doubled and reached 1µM in diabetic individuals with hyperalgesia 
which was associated with increased COX-2 expression and suppressed GLO-1 activity31.  
In mice, MGO induced heat hyperalgesia in a dose dependent manner when administered in 
WT mice31. Moreover, STZ diabetic mice showed GLO suppression which was associated 
withand hyperalgesia, and such complication was reproduced in WT mice when GLO 
expression was supressed31. MGO acutely depolarises the resting membrane potential in 
sensory neurons increasing their excitability. Such neuropathic events were shown to be 
NaV1.8 –dependent, as these events were absent in NaV1.8 –KO mice31Molecular studies 
showed MGO triggers changes in NaV1.8 gating through DIII-DIV linker’s arginine residue 
modification in mice dorsal root ganglion (DRG)31. 
Furthermore, MGO increases the release of calcitonin gene related peptide (CGRP) in 
peripheral nerves and nerve conduction in STZ-diabetic and control mice31. These neuronal 
events are also accompanied by an increase in cerebral blood flow to areas associated with 
nociception31.  
A further mechanism for exacerbation of diabetic neuropathy is activation by MGO of 
human ankyrin transient receptor potential TRPA1. An effect which was blocked by the  
TRPA1 antagonist (HC030031)13. TRPA1 is expressed in sensory neurons and mediates 
nociception through numerous noxious compounds such as the highly reactive electrophile, 
MGO. Binding of MGO to the cysteine and lysine residues of the channel’s N-terminal 
intracellular domain channel are necessary for channel activation by MGO13.  
Sensory neurons from TRPA1 knockout mouse shows no calcium influx when treated with 
MGO. MGO facilitates the release of CGRP from vagus and sciatic nerves as well as from the 
skin that contributes to pain transmission and together with PKA and PLC leads to nerve 
sensitization. MGO might contribute to neuropathic pain in diabetes13. 
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Table 1 Methylglyoxal effects on diabetes induction or diabetic complications  
Model  Diabetes related effect Significant findings 
Sprague-Dawley 
rats 
MGO 60mg/kg/day for 
28 days induces insulin 
dysfunction and 
hyperglycaemia and 
therefore is concluded 
as diabetogenic  
• Fasting plasma glucose elevation 
• Insulin release, GLUT-4, PI3-K and adipose 
glucose uptake reduction35 
Human insulin, 
cell culture 
studies on 3T3-
L1 adipocytes, 
L8 skeletal 
muscle cells, 
H4-II-E cells and 
INS-1E cells. 
MGO 10μM-1mM 
induces insulin 
resistance and thus is 
considered as 
diabetogenic  
• Mass spectrophotometry: additional peaks 
of MGO-bound insulin 
• L8-cells showed significant reduction in 
glucose uptake 
• MGO binds INS-1E cells and reduces Insulin 
negative feedback33 
RINmf5 insulin 
secreting cells 
MGO 100μM-10mM 
induces cells toxicity 
and thus is considered 
as diabetogenic  
• Fragmented nuclei cells elevation recorded 
microscopically and with multiparameter 
flow cytometry11  
Human plasma 
and 
erythrocytes  
MGO 30-300μM was 
shown to accelerate 
eryptosis  
• HPLC analysis showed plasma and RBC MGO 
elevation 
• MGO reduced GSH and ATP in RBC 
• MGO dose dependent annexin-V-positive 
elevation46 
Mouse aortic 
endothelial cells 
MGO 500μM induces 
endothelial 
dysfunction through 
interfering endothelial 
insulin signalling  
• Western blotting: Inhibiting IRS-1, Akt and 
eNOS phosphorylation37 
Human plasma MGO derivatives were 
associated with 
endothelial 
dysfunction  
• ELISA measurements showed sVCAM-1 and 
sPLA2 elevation associated with THP in 
T1DM patients44  
STZ Wistar-
Kyoto rats 
saphenous 
artery  
MGO elevation was 
associated with 
vascular function 
which is a major 
complication in 
diabetes  
• Mild impairment in cholinergic and sodium 
nitroprusside (SNP) induced vasodilation41 
Wistar and 
Goto-Kakizaki 
rats 
MGO induces 
endothelial 
dysfunction even 
when ingested (50-
75mg/kg/day for 3 
months)  
• Cholinergic vasodilation significant 
impairment 
• Aortic IHC showed significant reduction in 
free NO production accompanied with 
increase in superoxide generation  
• Western blotting showed significant 
suppression of phosphorylated and total 
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Conclusion: 
vasodilator stimulated phosphoprotein 
• Vascular inflammation through increased 
monocyte chemoattractant peptide-1 # 
(MCP-1)43 
Normal human 
LDL, human BJ 
fibroblast AND 
HepG2 cells and 
Charles River 
rats 
MGO-bound LDL 
accelerates vascular 
complications such as 
atherosclerosis 
• LDL particles significantly decreased through 
MGO binding 
• Cell free microplate blocked wells showed 
significant aggregation tendency of MGO-
bound LDL 
• IHC: MGO increased LDL retention in rats 
aorta 
• MGO-bound LDL binds significantly more to 
LDL receptors found on HepG2 and BJ cells49 
Sprague Dawley 
rat aortic rings, 
rat aortic and 
human 
umbilical veins 
endothelial 
cells.  
MGO 100μM induces 
endothelial 
dysfunction, a 
common diabetes 
complication  
• Cholinergic endothelium dependent 
vasodilation significant impairment 
accompanied with significant decrease in 
endothelial NO production with suppressed 
eNOS phosphorylation estimated through 
western blotting40 
Mice (TRPA1+/-) 
HEK 293t cells 
and DRG 
cultures 
MGO 10mM induces 
neuropathic pain, a 
major diabetic 
complication  
• MGO generates large inward current in HEK 
293t cells and depolarizes the membrane 
from -100 to +100mV  
• Calcium imaging reveals MGO binding to 
cysteine preferably to induce calcium entry 
• TRPA1 or TRPV1 KO DRG showed significant 
lack of response to MGO13  
Diabetic 
patients, WT 
and STZ mice 
mice (Glo-/+), 
mice (Scn-/-), 
human sciatic 
nerve, mice 
DRG, MGO 
treated Wistar 
rats 
MGO 5μM 
administered 
systemically into rats 
induces hyperalgesia 
and neuronal 
inflammation for 3 
hours  
• MGO elevation was associated with diabetic 
neuropathy in T2DM patients31  
• MGO depolarizes sensory neurons and 
modifies NaV1.8 to increase the neuronal 
excitation and facilitate nociception 
• MGO slows NaV1.7 inactivation 
• In mice, MGO reduces nerve conduction and 
increases calcitonin gene-related peptide 
(CGRP) and cyclooxygenase-2 (COX-2) 
expression to promote thermal and 
mechanical hyperalgesia in mice 
• MGO increases blood flow to nociceptive 
cerebral regions31 
Transgenic GLO-
1 and normal 
Wistar rats  
Restoring MGO 
metabolism prevents 
retinopathy, a 
common visual 
complication in 
diabetes  
• Immunoblotting showed significant increase 
in CEL, CML, MG-H1 in diabetic Wistar rats’ 
retinas suppressed in GLO1 transgenic rats45 
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Diabetes mellitus is a metabolic disorder that is a major health burden in most of the 
countries around the globe. Although numerous therapeutic options are available to control 
diabetes, these medications are targeted mainly toward controlling the blood glucose level 
through supplying insulin, enhancing insulin secretion, enhancing the tissues’ sensitivity 
towards insulin, interfering with glucose absorption or re-absorption. However, diabetic 
complications such as retinopathy, neuropathic pain, vascular and renal complications are 
still the main diabetic complications that, in the long term, remain largely resistant to 
treatments. Numerous studies reviewed in this paper show a correlation between MGO and 
diabetes as well as diabetes complications which suggest that understanding the actions of 
MGO might identify therapeutic targets for treating consequences of diabetes in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. References: 
18 
 
1. ADA, Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2012, 35 (1), S64-S71. 
2. UK, D., Diabetes: Facts and Stats. Diabetes UK 2014, 3, 1-21. 
3. Group, U. P. D. S., UK prospective diabetes study. Diabetologia 1991, 34 (12), 877-890. 
4. IDF Diabetes atlas. http://www.idf.org/diabetesatlas. 
5. Davies, M.; Brophy, S.; Williams, R.; Taylor, A., The Prevalence, Severity, and Impact of 
Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabetes Care 2006, 29 (7), 1518-1522. 
6. Hex, N.; Bartlett, C.; Wright, D.; Taylor, M.; Varley, D., Estimating the current and future 
costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and 
productivity costs. Diabetic Medicine 2012, 29 (7), 855-862. 
7. Ashcroft, F. M.; Rorsman, P., Diabetes mellitus and β-cells: the last ten years. Cell 2012, 148, 
1160-1171. 
8. Chao, E. C.; Henry, R. R., SGLT2 inhibition — a novel strategy for diabetes treatment. Nature 
Reviews Drug Discovery 2010, 9, 551-559. 
9. Menge, B. A.; Schrader, H.; Breuer, T. G. K.; Dabrowski, Y.; Uhl, W.; Schmidt, W. E.; Meier, J. 
J., Metabolic consequences of a 50% partial pancreatectomy in humans. Diabetologia 2009, 52, 306-
317. 
10. Del Guerra, S.; Lupi, R.; Marselli, L.; Masini, M.; Bugliani, M.; Sbrana, S.; Torri, S.; Pollera, M.; 
Boggi, U.; Mosca, F.; Del Prato, S.; Marchetti, P., Functional and molecular defects of pancreatic islets 
in human type 2 diabetes. Diabetes 2005, 54, 727-735. 
11. Sheader, E. A.; Benson, R. S. P.; Best, L., Cytotoxic action of methylglyoxal on insulin-
secreting cells. Biochemical Pharmacology 2001, 61, 1381-1386. 
12. Uchida, K., Role of reactive aldehyde in cardiovascular diseases. Free Radical Biology & 
Medicine 2000, 28 (12), 1685–1696. 
13. Eberhardt, M. J.; Filipovic, M. R.; Leffler, A.; De la Roche, J.; Kistner, K.; Fischer, M. J.; Flemin, 
T.; Zimmermann, K.; Burmazovic, I. I.; Nawroth, P. P.; Bierhaus, A.; Reeh, P.; Sauer, S. K., 
Methylglyoxal activates nociceptors through transient receptor potential A1 (TRPA1): a possible 
mechanism of metabolic neuropathies. JBC 2012, 287 (34), 28291-28306. 
14. Kalapos, M. P., Where does plasma methylglyoxal originate from? Diabetes Research and 
Clinical Practice 2012, 99 (3), 260-271. 
15. Lu, J.; Randell, E.; Han, Y.; Adeli, K.; Krahn, J.; Meng, Q. H., Increased plasma methylglyoxal 
level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clinical 
Biochemistry 2011, 44 (4), 307-311. 
16. Thornalley, P. J.; Jahan, I.; Ng, R., Suppression of the accumulation of triosephosphates and 
increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in 
vitro. J. Biochem 2001, 129 (4), 543-549. 
17. Jadidi, R. B.; Karachalias, N.; Ahmed, N.; Battah, S.; Thornalley, P. J., Prevention of incipient 
diabetic nephropathy by high dose thiamine and benfotiamine. Diabetes 2003, 52, 2110-2120. 
18. Hammes, H. P.; Du, X.; Edelstein, D.; Taguchi, T.; Matsumura, T.; Ju, Q.; Lin, J.; Bierhaus, A.; 
Nawroth, P.; Hannak, D.; Neumaier, M.; Bergfeld, R.; Giardino, I.; Brownlee, M., Benfotiamine blocks 
three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. 
Nature Medicine 2003, 9 (3), 294-299. 
19. Mahendran, Y.; Vangipurapu, J.; Cederberg, H.; Stančáková, A.; Pihlajamäki, J.; Soininen, P.; 
Kangas, A. J.; Paananen, J.; Civelek, M.; Saleem, N. K.; Pajukanta, P.; Lusis, A. J.; Bonnycastle, L. L.; 
Morken, M. A.; Collins, F. S.; Mohlke, K. L.; Boehnke, M.; Korpela, M. A.; Kuusisto, J.; Laakso, M., 
Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. 
Diabetes 2013, 62, 3618-3626. 
20. Lim, E. L.; Hollingsworth, K. G.; Smith, F. E.; Thelwall, P. E.; Taylor, R., Inhibition of lipolysis in 
type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rate. 
Clinical Science 2011, 121, 169-177. 
21. Arner, P.; Langin, D., Lipolysis in lipid turnover, cancer, cachexia, and obesity-induced insulin 
resistance. Trends in endocrinology and metabolism 2014, 25 (5), 255-262. 
19 
 
22. Jones, A. E.; Summers, R. L., Detection of isopropyl alcohol in a patient with diabetic 
ketoacidosis. The Journal of Emergency Medicine 2000, 19 (2), 165-168. 
23. Laffel, L., Ketone bodies: a review of physiology, pathophysiology and application of 
monitoring to diabetes. Diabetes Metab Res Rev 1999, 15, 412-426. 
24. Mitch, W. E.; Bailey, J. L.; Wang, X.; Jurkovitz, C.; Newby, D.; Price, S. R., Evaluation of signals 
activating ubiquitin-proteasome proteolysis in a model of muscle wasting. American Journal of 
Physiology 1999, 25 (5), C1132-C1138. 
25. Uribarri, J.; Negrean, M.; Stirban, A.; Buenting, C. E.; Sander, D.; Koschinsky, T.; Cai, W.; 
Vlassara, H., Single oral challenge by advanced glycation end products acutely impairs endothelial 
function in diabetic and nondiabetic subjects. Diabetes Care 2007, 30 (10), 2579-2582. 
26. Banning, M., The carcinogenic and protective effects of food. British Journal of Nursing 2005, 
14 (20), 1070-1074. 
27. Patel, R.; Baker, S. S.; Liu, W.; Desai, S.; Alkhouri, R.; Kozielski, R.; Mastrandrea, L.; Sarfraz, A.; 
Cai, W.; Vlassara, H.; Patel, M. S.; Baker, R. D.; Zhu, L., Effect of dietary advanced glycation end 
products on mouse liver. PLoS ONE 2012, 7 (4), 1-7. 
28. Goldberg, T.; Cai, W.; Peppa, M.; Dardaine, V.; Baliga, B. S.; Uribarri, J.; Vlassara, H., 
Advanced Glycoxidation End Products in Commonly Consumed Foods. Journal of the American 
Dietetic Association 2004, 104 (8), 1287–1291. 
29. Martins, S. I. F. S.; Jongen, W. M. F.; van Boekel, M. A. J. S., A review of Maillard reaction in 
food and implications to kinetic modelling. Trends in Food Science & Technology 2001, 11 (9-10), 
364-373. 
30. Dyer, D. G.; Dunn, J. A.; Thorpe, S. R.; Bailie, K. E.; Lyons, T. J.; McCance, D. R.; Baynes, J. W., 
Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993, 
91 (6), 2463-2469. 
31. Bierhaus, A.; Flemin, T.; Stoyanov, S.; Leffler, A.; Babes, A.; Neacsu, C.; Sauer, S. K.; 
Eberhardt, M.; Schnölzer, M.; Lasischka, F.; Neuhuber, W. L.; Kichko, T. I.; Konrade, I.; Elvert, R.; 
Mier, W.; Pirags, V.; Lukic, I. K.; Morcos, M.; Dehmer, T.; Rabbani, N.; Thornalley, P. J.; Edelstein, D.; 
Nau, C.; Forbes, J.; Humpert, P. M.; Schwaninger, M.; Ziegler, D.; Stern, D. M.; Cooper, M. E.; 
Haberkorn, U.; Brownlee, M.; Reeh, P. W.; Nawroth, P. P., Methylglyoxal modification of Nav1.8 
facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature 
Medicine 2012, 1-9. 
32. Miki, T.; Nagashima, K.; Tashiro, F.; Kotake, K.; Yoshitomi, H.; Tamamoto, A.; Gonoi, T.; 
Iwanaga, T.; Miyazaki, J.; Seino, S., Defective insulin secretion and enhanced insulin action in KATP 
channel-deficient mice. PNAS 1998, 95 (18), 10402–10406. 
33. Jia, S.; Olson, D. J. H.; Ross, A. R. S.; Wu, L., Structural and functional changes in human 
insulin induced by methylglyoxal. FASEB 2006, 20, E871-E879. 
34. Jia, X.; Wu, L., Accumulation of endogenous methylglyoxal impaired insulin signaling in 
adipose tissue of fructose-fed rats. Mol Cell Biochem 2007, 306, 133–139. 
35. Dhar, A.; Dhar, I.; Jiang, B.; Desai, K. M.; Wu, L., Chronic methylglyoxal infusion by minipump 
causes pancreatic β-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 
2011, 60, 899-908. 
36. Krüger, M.; Kratchmarova, I.; Blagoev, B.; Tseng, Y. H.; Kahn, C. R.; Mann, M., Dissection of 
the insulin signaling pathway via quantitative phosphoproteomics. PNAS 2007, 105 (7), 2451–2456. 
37. Nigro, C.; Raciti, G. A.; Leone, A.; Flemin, T. H.; Longo, M.; Prevenzano, I.; Fiory, F.; Mirra, P.; 
D’Esposito, V.; Ulianich, L.; Nawroth, P. P.; Formisano, P.; Beguinot, F.; Miele, C., Methylglyoxal 
impairs endothelial insulin sensitivity in both in vitro and in vivo. Diabetologia 2014, 57, 1485–1494  
38. Taniguchi, C. M.; Emanuelli, B.; Kahn, C. R., Critical nodes in signalling pathways: insights into 
insulin action. Nature Reviews Molecular Cell Biology 2006, 7, 85-96. 
39. Chang, W.; Wang, R.; Wu, L., Methylglyoxal-induced nitric oxide and peroxynitrite 
production in vascular smooth muscle cells. Free Radical Biology & Medicine 2005, 38, 286-293. 
20 
 
40. Dhar, A.; Dhar, I.; Desai, K. M.; Wu, L., Methylglyoxal scavengers attenuate endothelial 
dysfunction induced by methylglyoxal and high concentrations of glucose. British Journal of 
Pharmacology 2010, 161, 1843–1856. 
41. Ruiter, M. S.; Van Golde, J. M.; Schaper, N. C.; Stehouwer, C. D.; Huijberts, M. S., The role of 
methylglyoxal in hyperglycemia-induced impairments of vasoreactivity in rat saphenous artery. In 
Reactivity, recruitment and remodeling of collateral arteries in diabetes, Ruiter, M. S., Ed. Gildeprint 
Drukkerijen: Amsterdam, 2012; pp 83-98. 
42. Oya, T.; Hattori, N.; Mizuno, Y.; Miyata, S.; Maeda, S.; Osawa, T.; Uchida, K., Methylglyoxal 
modification of Protein: chemical and immunochemical characterization ofmethylglyoxal-arginine 
adducts. JBC 1999, 274 (26), 18492-18502. 
43. Sena, C. M.; Matafome, P.; Crisóstomo, J.; Rodrigues, L.; Fernandes, R.; Pereira, P.; Seic¸a, R. 
M., Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacological Research 
2012, 65, 497-506. 
44. van Eupen, M. G. A.; Scharm, M. T.; Colhoun, H. M.; Hansen, N. M. J.; Niessen, H. W. M.; 
Tarnow, L.; Parving, H. H.; Rossing, P.; Stehouwer, C. D. A.; Schalkwijk, C. G., The methylglyoxal-
derived AGE tetrahydropyrimidineis increased in plasma of individuals with type 1 diabetes mellitus 
and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia 2013, 56, 1845-1855. 
45. Berner, A. K.; Brouwers, O.; Pringle, R.; Klaassen, I.; Colhoun, L.; McVicar, C.; Brockbank, S.; 
Curry, J. W.; Miyata, T.; Brownlee, M.; Schlingemann, R. O.; Schalkwijk, C.; Stitt, A. W., Protection 
against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and 
vasodegenerative pathology. Diabetologia 2012, 55, 845-854. 
46. Nicolay, J. P.; Schneider, J.; Niemoeller, O. M.; Artunc, F.; Otin, M. P.; Haik Jr., G.; Thornalley, 
P. J.; Schleicher, E.; Wieder, T.; Lang, F., Stimulation of suicidal erythrocyte death by methylglyoxal. 
Cell Physiol Biochem 2006, 18, 223-232. 
47. Föller, M.; Huber, S. M.; Lang, F., Erythrocyte Programmed Cell Death. IUBMB Life 2008, 60 
(10), 661-668. 
48. Latscha, D. B.; Drüeke, T.; Sarsat, V. W., Dialysis-induced oxidative stress: biological aspects 
and, clinical consequences, and therapy. Seminars in Diabaetes 2001, 14 (3), 193-199. 
49. Rabbani, N.; Godfrey, L.; Xue, M.; Shaheen, F.; Geoffrion, M.; Milne, R.; Thornalley, P. J., 
Glycation of LDL by methylglyoxal increases arterial atherogenicity. Diabetes 2011, 60, 1973-1980. 
 
